Skip to main content

Advertisement

Table 1 Clinical characteristics of 148 patients by the LMR level at diagnosis

From: The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma

Characteristic No. (%) Low LMR group LMR ≤ 2.7 High LMR group LMR > 2.7
Gender
 Male 91 (61.5) 22 (14.9) 69 (46.6)
 Female 57 (38.5) 15 (10.1) 42 (28.4)
Age (year)
 > 60 18 (12.2) 6 (4.1) 12 (8.1)
 ≤ 60 130 (87.8) 31 (20.9) 99 (66.9)
B symptoms
 Absent 65 (43.9) 14 (9.5) 51 (34.5)
 Present 83 (56.1) 23 (15.5) 60 (40.5)
Lugano stage
 I–II2 119 (80.4) 22 (14.9) 97 (65.5)
 III–IV 29 (19.6) 15 (10.1) 14 (9.5)
ECOG PS
 < 2 143 (96.6) 35 (23.6) 108 (73.0)
 ≥ 2 5 (3.4) 2 (1.4) 3 (2.0)
LDH
 Normal 107 (72.3) 23 (15.5) 84 (56.8)
 Abnormal 41 (27.7) 14 (9.5) 27 (18.2)
IPI score
 0–2 137 (92.6) 32 (21.6) 105 (70.9)
 3–5 11 (7.4) 5 (3.4) 6 (4.1)
Distant metastasis
 Yes 97 (65.5) 22 (14.9) 65 (43.9)
 No 51 (35.5) 15 (10.1) 36 (24.3)
Chemotherapy regimen
 DIE-L 59 (39.9) 45 (30.4) 14 (9.5)
 GDP-L 37 (25.0) 28 (18.9) 9 (6.1)
 CHOP-L 22 (14.9) 17 (11.5) 5 (3.4)
 SMILE 19 (12.8) 13 (8.8) 6 (4.1)
 P-Gemox 6 (4.1) 4 (2.7) 2 (1.4)
  1. DIE-L ifosfamide, etoposide, dexamethasone, and l-asparaginase, GDP-L gemcitabine, dexamethasone, cisplatin, and l-asparaginase, CHOP-L cyclophosphamide, doxorubicin, vincristine, prednisolone, and l-asparaginase, SMILE dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide, P-Gemox gemcitabine, oxaliplatin, and pegaspargase